Search

Filters
Types

Sign up for our free
equity research notes

Register
523 Results for ‘biotech growth’
Embed
QuotedData’s investment companies roundup – June 2019

Investment Companies Roundup  New research Over May, we published notes on Shires Income, Standard Life Private Equity and The North American Income Trust. You can read all these notes by clicking on the links above or by visiting www.quoteddata.com.  In this issue Performance data – it was notable that risk appetite was down in May as renewed […]

QuotedData’s economic roundup – June 2019

Economic & Political Roundup A collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or sell any of the […]

QuotedData’s other news 28 May 2019

In QuotedData’s other news 28 May 2019: A new fund – Riverstone Credit Opportunities : RCOI – starts trading today, having raised $100m from professional investors to lend money to energy (mainly oil and gas) companies CQS New City High Yield announced that an administrative error had led to it overstating its NAV between 25 April […]

QuotedData’s investment companies roundup – May 2019

Investment Companies Roundup  New research Over April, we published notes on Henderson Diversified Income, Ecofin Global Utilities and Infrastructure, Jupiter Emerging and Frontier Income, Seneca Global Income & Growth and Polar Capital Global Financials Trust. You can read all these notes by clicking on the links above or by visiting www.quoteddata.com.  In this issue Performance data – it was […]

QuotedData’s investment companies roundup – February 2019

QuotedData’s investment companies roundup – February 2019 is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of January 2019. Kindly sponsored by Baillie Gifford. December’s sharp sell-off in technology and growth stocks reversed somewhat in January. This was […]

QuotedData’s investment companies roundup – November 2018

QuotedData’s investment companies roundup – November 2018 is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of October 2018. Kindly sponsored by Baillie Gifford. Winners and losers in October In what was generally a miserable month for equity markets, Brazil shone […]

IP Group-backed Genomics raises £25m in a Series B

IP Group-backed Genomics raises £25m in a Series B Genomics plc, a University of Oxford spin-out backed by UK-based healthcare/tech VC investor IP Group (LSE: IPO), has closed a £25.0m Series B financing round led by the major US biotech, Vertex Pharmaceuticals.  Woodford Investment Management – manager of the Woodford Patient Capital Trust (WPCT) – Invesco Perpetual, Oxford […]

IP Group-backed Genomics raises £25m in a Series B
Trust favourite Alnylam gains on competitor data

Biotech trust stock favourite Alnylam Pharmaceuticals (Nasdaq: ALNY) gained more than 16% yesterday after the presentation of ostensibly highly positive clinical trial data on one of its key competitors at a scientific meeting. Alnylam is held by several of the sector’s specialist investment trusts including Biotech Growth (BIOG, 3.6% of NAV) and BB Biotech (BBB, 3.6% of NAV) […]

Trust favourite Alnylam approaches key FDA decision
Trust favourite Gilead gears up for filgotinib RA Phase III data

Trust favourite Gilead gears up for filgotinib RA Phase III data Gilead Sciences, a widely held stock among biotech investment trusts and a top 10 holding for BB Biotech (BBB, 5.1% of NAV) and Biotech Growth Trust (BIOG, 3.9%), is expected  to report top-line results from two trials involving its JAK 1 selective inhibitor filgotinib in rheumatoid arthritis (RA) and in ankylosing […]

Trust favourite Gilead gears up for filgotinib RA Phase III data 1
Alnylam receives expected FDA ok for Onpattro

Alnylam receives expected FDA ok for Onpattro Biotech trust stock favourite Alnylam Pharmaceuticals (Nasdaq: ALNY) received its  first FDA approval late on Friday for Onpattro (patisiran) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. However, the FDA did not allow a broader label that included patients with cardiomyopathy (CM), leading to […]

Trust favourite Alnylam approaches key FDA decision

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…